NCT07522645

Brief Summary

The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes. The main questions it aims to answer are:

  • Receive an initial outreach message encouraging statin refill (or usual care) Be monitored for statin refill within 14 days
  • Potentially receive a second outreach message using the same or a different communication method if they do not initially refill their prescription
  • Have their medication refill patterns tracked over time, including longer-term adherence outcomes

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22,000

participants targeted

Target at P75+ for not_applicable

Timeline
29mo left

Started Apr 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Apr 2026Dec 2028

First Submitted

Initial submission to the registry

April 2, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 13, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

April 14, 2026

Completed
28 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 12, 2026

Completed
2.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Expected
Last Updated

July 6, 2026

Status Verified

April 1, 2026

Enrollment Period

28 days

First QC Date

April 2, 2026

Last Update Submit

July 1, 2026

Conditions

Keywords

ASCVDASCVD managementstatin therapystatinSMART designmessaging strategiespatient outreach

Outcome Measures

Primary Outcomes (1)

  • Statin refill after message delivery

    Proportion of participants who refill a statin prescription following message delivery (first-stage intervention) or, among non-responders, following second-stage messaging. Refill status will be determined using pharmacy dispensing records.

    Within 14 days after each stage of message delivery

Secondary Outcomes (4)

  • Time to statin refill

    Up to 30 days after each stage of message delivery

  • Statin refill

    Within 30 days after message delivery

  • Statin persistence

    At 6 months and 12 months post randomization.

  • Statin adherence (proportion of days covered)

    At 6 months and 12 months post randomization.

Study Arms (13)

SMS/SMS

EXPERIMENTAL

Participants in this arm will receive an initial SMS (text message) encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a second SMS.

Behavioral: SMS (Initial Outreach)Behavioral: SMS (Follow-up for Non-responders)

SMS/Secure Portal Message

EXPERIMENTAL

Participants in this arm will receive an initial SMS (text message) encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a secure portal message.

Behavioral: SMS (Initial Outreach)Behavioral: Secure Portal Message (Follow-up for Non-responders)

SMS/Non-secure Email

EXPERIMENTAL

Participants in this arm will receive an initial SMS (text message) encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a non-secure email.

Behavioral: SMS (Initial Outreach)Behavioral: Non-secure Email (Follow-up for Non-responders)

SMS/Usual Care

EXPERIMENTAL

Participants in this arm will receive an initial SMS (text message) encouraging statin refill. Participants who do not refill their prescription within 14 days will receive no additional outreach (usual care).

Behavioral: SMS (Initial Outreach)

Secure Portal Message/Secure Portal Message

EXPERIMENTAL

Participants in this arm will receive an initial secure portal message encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a second secure portal message.

Behavioral: Secure Portal Message (Initial Outreach)Behavioral: Secure Portal Message (Follow-up for Non-responders)

Secure Portal Message/SMS

EXPERIMENTAL

Participants in this arm will receive an initial secure portal message encouraging statin refill. Participants who do not refill their prescription within 14 days will receive an SMS (text message).

Behavioral: Secure Portal Message (Initial Outreach)Behavioral: SMS (Follow-up for Non-responders)

Secure Portal Message/Non-secure Email

EXPERIMENTAL

Participants in this arm will receive an initial secure portal message encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a non-secure email.

Behavioral: Secure Portal Message (Initial Outreach)Behavioral: Non-secure Email (Follow-up for Non-responders)

Secure Portal Message/Usual Care

EXPERIMENTAL

Participants in this arm will receive an initial secure portal message encouraging statin refill. Participants who do not refill their prescription within 14 days will receive no additional outreach (usual care).

Behavioral: Secure Portal Message (Initial Outreach)

Non-secure Email/Non-secure Email

EXPERIMENTAL

Participants in this arm will receive an initial non-secure email encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a second non-secure email.

Behavioral: Non-secure Email (Initial Outreach)Behavioral: Non-secure Email (Follow-up for Non-responders)

Non-secure Email/SMS

EXPERIMENTAL

Participants in this arm will receive an initial non-secure email encouraging statin refill. Participants who do not refill their prescription within 14 days will receive an SMS (text message).

Behavioral: Non-secure Email (Initial Outreach)Behavioral: SMS (Follow-up for Non-responders)

Non-secure Email/Secure Portal Message

EXPERIMENTAL

Participants in this arm will receive an initial non-secure email encouraging statin refill. Participants who do not refill their prescription within 14 days will receive a secure portal message.

Behavioral: Non-secure Email (Initial Outreach)Behavioral: Secure Portal Message (Follow-up for Non-responders)

Non-secure Email/Usual Care

EXPERIMENTAL

Participants in this arm will receive an initial non-secure email encouraging statin refill. Participants who do not refill their prescription within 14 days will receive no additional outreach (usual care).

Behavioral: Non-secure Email (Initial Outreach)

Usual Care/Usual Care

NO INTERVENTION

Participants in this arm will receive usual care with no proactive outreach during the study period.

Interventions

Participants will receive an initial SMS (text message) encouraging statin refill. Messages may include reminder prompts and interactive features implemented through automated keyword-triggered responses that provide refill instructions or educational information.

SMS/Non-secure EmailSMS/SMSSMS/Secure Portal MessageSMS/Usual Care

Participants will receive an initial secure message through the kp.org patient portal encouraging statin refill. Messages are delivered within the secure portal environment and may include informational and reminder content.

Secure Portal Message/Non-secure EmailSecure Portal Message/SMSSecure Portal Message/Secure Portal MessageSecure Portal Message/Usual Care

Participants will receive an initial non-secure email encouraging statin refill. Emails may include informational content and reminders but are delivered outside of the secure patient portal.

Non-secure Email/Non-secure EmailNon-secure Email/SMSNon-secure Email/Secure Portal MessageNon-secure Email/Usual Care

Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up SMS (text message) encouraging statin refill. Messages may include reminder prompts and interactive features implemented through automated keyword-triggered responses that provide refill instructions or educational information.

Non-secure Email/SMSSMS/SMSSecure Portal Message/SMS

Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up secure portal message through the kp.org patient portal encouraging statin refill. Messages are delivered within the secure portal environment and may include informational and reminder content.

Non-secure Email/Secure Portal MessageSMS/Secure Portal MessageSecure Portal Message/Secure Portal Message

Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up non-secure email encouraging statin refill. Emails may include informational content and reminders but are delivered outside of the secure patient portal.

Non-secure Email/Non-secure EmailSMS/Non-secure EmailSecure Portal Message/Non-secure Email

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥18 years
  • Active Kaiser Permanente Northern California (KPNC) membership
  • No statin prescription fill within the prior 3 months
  • Statin adherence \<80% in the prior 12 months
  • Active kp.org account within the past 12 months
  • Valid email address and text-capable phone number on file

You may not qualify if:

  • Documented allergic reaction or contraindication to statin therapy
  • Receiving hospice care
  • Medicare beneficiaries

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kaiser Permenante Northern California

Pleasant Hill, California, 94588, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus

Interventions

Spermine Synthase

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Alkyl and Aryl TransferasesTransferasesEnzymesEnzymes and Coenzymes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
SEQUENTIAL
Model Details: Two-stage, sequential multiple assignment randomized trial (SMART)
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 2, 2026

First Posted

April 13, 2026

Study Start

April 14, 2026

Primary Completion

May 12, 2026

Study Completion (Estimated)

December 31, 2028

Last Updated

July 6, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations